$EOSE

Shareholder lawsuits target Kyndryl and uniQure with lead plaintiff deadlines approaching April 2026. Investors must act quickly to join litigation.

$EOSE faces class action lawsuit over alleged false production capacity and performance claims. Lead plaintiff deadline: May 5, 2026.

Class action lawsuit filed against Eos Energy Enterprises ($EOSE) alleging executives made false statements about production capacity, battery downtime, and quality issues from November 2025 to February 2026.

Class action filed against $EOSE alleging materially false statements and non-disclosure of production delays, battery downtime, and quality control failures.

Eos Energy Enterprises ($EOSE) faces securities lawsuit after missing revenue guidance by $35-46M, citing production issues. May 5, 2026 deadline for investor claims.

Class action lawsuit filed against $EOSE over missed production targets and guidance misses. Stock crashed 39% after $970M loss reported.

EOSE shares plunged 39% after missing FY 2025 revenue targets by 25% and revealing manufacturing delays. Securities lawsuit alleges management concealed production issues from investors.

Rosen Law Firm alerts $EOSE investors of May 5 deadline to join securities lawsuit alleging false production capacity and guidance statements.

Class action lawsuit filed against $EOS alleging securities fraud over undisclosed production delays, quality control issues, and inadequate guidance during Nov 2025-Feb 2026 period.

$EOSE plummeted 39% after revealing 25% FY2025 revenue shortfall and production problems. Securities lawsuit alleges management concealed scaling issues from investors.

Eos Energy Enterprises faces class action lawsuit alleging undisclosed production ramp failures and quality issues misled investors between November 2025 and February 2026.

Rosen Law Firm files securities class action against REGENXBIO for alleged false statements on product safety and efficacy, with April 14, 2026 lead plaintiff deadline.

Shareholder lawsuits against Nektar Therapeutics ($NKTR) and Eos Energy ($EOSE) allege clinical trial and production capacity disclosure failures, with lead plaintiff deadlines in April-May 2026.

Aldeyra Therapeutics ($ALDX) shares crashed 65% following FDA rejection of reproxalap for dry eye disease. Law firm Block & Leviton investigates potential securities fraud.

Rosen Law Firm files class action against $EOSE for alleged false statements on production capacity and guidance. Lead plaintiff deadline: May 5, 2026.

Class action lawsuit filed against $EOSE alleging securities fraud over undisclosed production delays, battery quality issues, and false guidance during November 2025-February 2026 period.

Grabar Law Office investigates securities fraud claims against $ASPI, $CWH, $EOSE, and $SLNO for alleged disclosure failures. Long-term shareholders may seek compensation and reforms at no cost.

Eos Energy Enterprises faces class action lawsuit after 2025 revenue missed guidance by 24%, falling to $114.2M. Stock collapsed 39%; investors can claim lead plaintiff status by May 5, 2026.

Robbins Geller launches class action lawsuit against $SNOW, alleging securities fraud over false product efficiency claims and material business disclosures between June 2023 and February 2024.

Three companies face class action lawsuits alleging securities fraud. Boston Scientific stock fell 17% after missing earnings guidance amid alleged false revenue projections.